Concurrent chemotherapy and proton therapy improves survival in patients with advanced lung cancer

Share it with your friends Like

Thanks! Share it with your friends!

Close

Dr. Steven Frank, medical director at the MD Anderson Proton Therapy Center, and Dr. Joe Y. Chang, professor of Radiation Oncology, discuss a recent study on how concurrent chemotherapy and proton therapy improves survival in patients with advanced lung cancer.

The study opened at MD Anderson in 2006, and in this research, Dr. Chang and his colleagues report on the study’s five-year results. The findings are the final results of the single institution, Phase II study and represent the longest follow-up to date of stage 3 lung cancer patients who have received proton therapy.

“With our study, we hypothesized that proton therapy would offer a survival benefit to patients and reduce treatment-associated toxicities, which can be very serious,” explained Chang.

Read more: http://bit.ly/2E4HSBS

Request an appointment at MD Anderson by calling 1-877-632-6789 or online at: https://my.mdanderson.org/RequestAppointment?cmpid=youtube_appointment_proton

Comments

Write a comment